Open AccessAlternative clinical indications for novel antibiotics licensed for skin and soft tissue infection?
Author(s) -
Matthew Dryden
Publication year - 2015
Publication title -
current opinion in infectious diseases/current opinion in infectious diseases, with evaluated medline
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.68
H-Index - 103
eISSN - 1080-7861
pISSN - 0951-7375
DOI - 10.1097/qco.0000000000000142
Subject(s) - dalbavancin , medicine , tigecycline , linezolid , daptomycin , clinical trial , antibiotics , intensive care medicine , skin infection , adverse effect , clinical efficacy , dermatology , surgery , staphylococcus aureus , microbiology and biotechnology , vancomycin , bacteria , genetics , biology
A number of novel antibiotics in different classes have been registered and licensed in recent years for complicated skin and soft tissue infections or acute bacterial skin and skin structure infections. Many of these have activity against resistant gram-positive bacteria (linezolid, daptomycin, oritavancin, dalbavancin and tedizolid). In addition, two have gram-negative activity (ceftaroline and tigecycline). The licence for the clinical use of these agents is very narrow, but the clinical need is much broader. This is a personal opinion of the prospective clinical roles for these novel antibiotics.